Opus Genetics raises $23M in direct offering and secures FDA guidance for LCA5 gene therapy trial

Opus Genetics, Inc.

$23M registered direct offering led by Perceptive Advisors and Balyasny Asset Management; closes Nov 7, 2025.
Offering: 3.83M shares at $2.09/sh and pre-funded warrants for 7.18M shares at $2.0899.
FDA RMAT meeting provides guidance on registration strategy; Phase 3 design adaptive, as few as 8 participants.
Phase 1/2 data: all 6 late-stage participants achieved clinically meaningful vision improvements.
First participant enrolled in run-in; dosing H2 2026, topline ~1 year later; cash runway into H2 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.